

Regulation of Mitochondrial Function and Energy Metabolism: A Primary Mechanism of Cytoprotection Provided by Carnosine

Reza Heidari¹, Vahid Ghanbarinejad^{1,2}, Mohammad Mehdi Ommati¹, Akram Jamshidzadeh^{1,2}, Hossein Niknahad^{1,2,*}

¹Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz Iran

²Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz Iran.

Abstract

Carnosine is a dipeptide abundantly found in different tissues. Several pharmacological properties have been attributed to carnosine. On the other hand, the precise mechanism of cytoprotection provided by carnosine remains obscure. The current study aimed to evaluate the direct effect of different concentrations of carnosine on cellular mitochondria as an essential target involved in cytoprotection or cytotoxicity. Liver mitochondria were isolated and exposed to carnosine (0.01-20 mM). Mitochondrial depolarization, dehydrogenases activity, reactive oxygen species (ROS) formation, mitochondrial swelling and permeability, and ATP content were assessed. On the other hand, the effect of carnosine supplementation on calcium (Ca^{2+}) overload-induced mitochondrial injury was evaluated. It was found that concentrations between 0.01-20 mM of this peptide preserved mitochondrial indices of functionality in a Ca^{2+} overloaded environment. These data represent regulation of mitochondrial function as a primary mechanism for the protective properties of carnosine.

Keywords: Apoptosis; Bioenergetics; Cell death; Cytoprotective; Peptide.

1. Introduction

Carnosine (β -alanyl-L-histidine; CA) is a dipeptide widely investigated for its physiological as well as pharmacological roles (1, 2). CA is present at high concentrations in human skeletal and cardiac muscle, brain, kidney, stomach, and olfactory bulbs (3-5). Several biological roles have been identified for CA and its associated compounds (6-9). Antioxidant and reactive species scavenging properties are essential characteristics of CA which are firmly attributed to the protective properties of this molecule (3, 10-12). CA is an excellent scavenger of reactive oxygen species including singlet oxygen, hydroxyl and superoxide radicals (3, 13, 14). Some investigations men-

tioned that CA effectively blunts biomembrane disruption both at cellular and organelle level (3, 13, 14). CA is also repeatedly investigated for its protective properties against a wide range of diseases and xenobiotic-induced toxicity (15-20). On the other hand, the direct effect of CA on isolated mitochondria has not been evaluated so far.

Several investigations mentioned the positive effects of CA on mitochondria (21-23). It has been found that CA effectively preserves mitochondrial membrane potential, regulates mitochondrial matrix pH, and enhances mitochondrial defense mechanisms (21-23). Hence, a significant part of cytoprotection provided by CA might be mediated through its effects on cellular mitochondria. On the other hand, the involvement of the mitochondria in regulating cytoplasmic Ca^{2+} level has been well-established (24). Cellular ROS formation and

Corresponding Author: Hossein Niknahad, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Email: niknahadh@sums.ac.ir

oxidative stress, mitochondrial dysfunction, and Ca^{2+} overload are well-known mechanistically interconnected events which finally lead to cell death (24). In the current study, Ca^{2+} was used as a stressor to test the mitochondria-protecting properties of CA.

The current study was designed to evaluate the direct effect of CA on cellular mitochondria and investigate the effect of different concentrations of carnosine on this organelle aimed at understanding the mechanism(s) of CA cytoprotection.

2. Materials and methods

2.1 Chemicals

Carnosine was purchased from Sigma (St. Louis, MO, USA). 4,2 Hydroxyethyl,1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino) propane sulfonic acid (MOPS), Sucrose, Dimethyl sulfoxide (DMSO), D-mannitol, Bovine serum albumin (BSA; Fatty acid free), Thiobarbituric acid (TBA), 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), Rhodamine 123 (Rh 123), Coomassie brilliant blue, Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), Hydroxymethyl amino methane hydrochloride (Tris-HCl), Sodium succinate, and Ethylenediaminetetraacetic acid (EDTA) were purchased from Merck (Darmstadt, Germany). All salts (Analytical grade) for preparing buffer solutions were purchased from Merck (Darmstadt, Germany).

2.2. Animals

Male BALB/c mice (20-30 g) were obtained from Animal Breeding Center of Shiraz University of Medical Sciences, Shiraz, Iran. Mice were housed in cages on wood-chip bedding at a temperature of 23 ± 2 °C and relative humidity of $\approx 40\%$. Animals had free access to tap water and a standard chow diet (Behparvar[®], Tehran, Iran). Mice were handled according to the animal handling protocol approved by the local ethics committee at Shiraz University of Medical Sciences, Shiraz, Iran (#15034).

2.3. Liver Mitochondria isolation

Mice liver mitochondria were isolated as

previously described (25). Briefly, animals were anesthetized (ketamine/xylazine, 50/10 mg/kg, i.p) and their liver was excised and washed with ice-cold sodium chloride (saline 0.9%) (25, 26). The liver was homogenized in a buffer solution containing 225 mM sucrose, 70 mM mannitol, 0.5 mM EGTA, 0.1% essential fatty acid-free bovine serum albumin (BSA), 2 mM HEPES (pH=7.4), at a 10:1 buffer to liver tissue (v/w) ratio (20, 25). Afterwards, the liver homogenate was centrifuged at $1,000 \times g$ for 10 minutes at 4 °C to remove intact cells and nuclei. The supernatants were further centrifuged ($15,000 \times g$, 4 °C, 10 minutes) to help precipitate the heavy membrane fractions (mitochondria) (27, 28). This step was repeated four times using fresh buffer medium. As mentioned, all manipulations for liver mitochondria isolation were performed at 4 °C or on ice to minimize mitochondrial injury (25).

2.4. Mitochondrial Swelling assay

Mitochondrial swelling was assessed using the light scattering method (25). For this purpose, the isolated mitochondria were suspended in a buffer containing 125 mM sucrose, 65 mM KCl, 10 mM Hepes-KOH, and pH=7.2 (29, 30). Light absorbance at $\lambda=540$ nm was monitored (Constant temperature of 30 °C) with a FLUOstar Omega[®] multifunctional fluorescent microplate reader (25, 31, 32). It is accepted that a decrease in light absorbance is related to the increase in mitochondrial volume (32). Therefore, as mitochondria are more swelled, the differences between light absorbance of the two time points are higher. The differences between the absorbance of samples at $\lambda=540$ nm (ΔOD_{540} nm) were determined and the results were reported as mitochondrial maximal swelling amplitude (25, 32).

2.5. Mitochondrial membrane potential

The uptake of the cationic fluorescent dye, rhodamine 123 by polarized mitochondria, was used for the estimation of mitochondrial membrane potential (25, 33). For this purpose, the mitochondrial fractions (0.5 mg protein/ml) were incubated with rhodamine 123 (Final concentration of 10 μM) in a buffer solution containing 125 mM sucrose, 65 mM KCl, 10 mM HEPES, pH=7.2 (30

min, 37 °C, in the dark) (32, 33). Samples were centrifuged (10,000 g, 1 minute, 4 °C) and the fluorescence intensity of the supernatant was monitored using a FLUOstar Omega[®] multifunctional fluorescent microplate reader at the $\lambda_{\text{excitation}}=485$ nm and $\lambda_{\text{emission}}=525$ nm (25, 34).

2.6. Mitochondrial ATP level

A luciferase-luciferin-based kit (Promega ENLITEN[®]) was used to determine mitochondrial ATP reservoirs (20, 35). Buffer solutions and mitochondrial samples were prepared based on the kit instructions. Finally, the luminescence intensity of samples was assessed at $\lambda=560$ nm using a FLUOstar Omega[®] multifunctional microplate reader (36). For standardization of the data, the protein concentrations of samples were determined by the Bradford method (37).

2.7. Mitochondrial dehydrogenases assay

A colorimetric method based on the reduction of the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was applied for the determination of mitochondrial dehydrogenases activity (32, 38). Briefly, mitochondrial suspension in a buffer solution (1 mM EDTA, 320 mM sucrose, and 10 mM Tris-HCl, pH=7.4), was incubated with 40 μ l of MTT (0.4% w:v; 37 °C for 30 minutes, in the dark) (39, 40). Then, samples were centrifuged (10,000 g, 5 minutes) and the product of purple formazan crystals was dissolved in 1 ml dimethyl sulfoxide (DMSO). Afterwards, 0.1 ml of the dissolved formazan was added to a 96 well plate. Finally, the optical density (OD) at $\lambda=570$ nm was measured with an EPOCH plate reader (BioTek[®] Instruments, Highland Park, USA) (32, 38).

2.8. Reactive oxygen species (ROS) in isolated liver mitochondria

The ROS measurement was performed using the fluorescent probe DCFH-DA (25, 41-43). Briefly, isolated liver mitochondria were incubated in a respiratory buffer solution containing 125 mM sucrose, 65 mM KCl, 10 mM HEPES, 20 μ M Ca^{2+} , sodium succinate 5 mM, pH=7.2 (25). Following this step, DCFH-DA was added (Final concentration, 10 μ M) to mitochondria and then incu-

bated for 30 min at 37 °C. Then, the fluorescence intensity of DCF was measured using a FLUOstar Omega[®] multifunctional fluorescent microplate reader ($\lambda_{\text{excitation}}=485$ nm and $\lambda_{\text{emission}}=525$ nm) (25).

2.9. Statistical analysis

Data are given as the Mean \pm SD. Data comparison was performed by the one-way analysis of variance (ANOVA) with Tukey's multiple comparison test as the post hoc. Differences were considered statistically significant when P-value <0.05.

3. Results

Isolated liver mitochondria were incubated with different concentrations of CA (0.01 mM-160 mM). CA treatment (0.01-10 mM) significantly enhanced mitochondrial indices of functionality in isolated mice liver mitochondria (Figure 1). It was found that CA administration (0.01-10 mM) improved mitochondrial membrane potential, promoted mitochondrial ATP metabolism, and increased mitochondrial dehydrogenases activity (Figure 1).

The mitochondrial protecting properties of CA was also assessed in a Ca^{2+} -overloaded environment. For this purpose, isolated mitochondria were incubated with Ca^{2+} (200 μ M) and CA (0.01-20 mM; 30 minutes before Ca^{2+}) (Figures 2 and 3). It was found that CA supplementation (0.01, 0.05, 0.1 and 1 mM) significantly prevented Ca^{2+} -induced mitochondrial dysfunction as judged by higher ATP content, increased mitochondrial dehydrogenases activity, and prevention of mitochondrial depolarization in CA-treated groups (Figures 2 and 3). Moreover, mitochondrial permeabilization and ROS formation were significantly lower in CA-treated isolated mitochondria (Figures 2 and 3).

4. Discussion

Carnosine (CA) is a dipeptide abundantly found in different mammalian tissues. Several physio/pharmacological roles are attributed to this peptide. It has been established that CA counteracts reactive oxygen and nitrogen species (1, 10, 13, 44, 45), chelates metal ions (46, 47), and pro-




Figure 1. Concentration-response of carnosine on mitochondrial indices of functionality.

Data are given as Mean±SD (n=8).

*Indicates significantly different as compared with control (0 mM carnosine) ($P<0.01$).

protects biological systems against oxidative stress and its deleterious consequences (1, 10, 13, 44, 45). Another essential physiological role for CA includes intracellular pH control (48, 49). The effect of this peptide on different systems including cardiovascular, immune, and renal systems has been widely investigated (44, 50-52). Despite the

tremendous physiological and pharmacological effects assigned to CA, its precise mechanism(s) of cytoprotection/toxicity remains unclear. The current study was designed to investigate the impact of various CA concentrations on cellular mitochondria as a significant target for cytoprotection/cytotoxicity.




Figure 2. Calcium (Ca^{2+})-induced mitochondrial permeabilization and swelling in the presence of carnosine.

Data are given as Mean±SD (n=8).

***Indicates significantly different as compared with control ($P<0.001$).

^aIndicates significantly different as compared with Ca^{2+} 200 μM ($P<0.001$).

^bIndicates significantly different as compared with Ca^{2+} 200 μM ($P<0.05$).

ns: not significant as compared with Ca^{2+} 200 μM ($P>0.05$).




Figure 3. Effect of carnosine on Ca²⁺-induced mitochondrial dysfunction.

Isolated liver mitochondria were incubated with Ca²⁺ (200 μM) alone or in combination with carnosine. Carnosine was added 15 minutes before Ca²⁺ challenge. Data are given as Mean±SD (n=8).

***Indicates significantly different as compared with control ($P<0.001$).

^aIndicates significantly different as compared with Ca²⁺ 200 μM ($P<0.001$).

^bIndicates significantly different as compared with Ca²⁺ 200 μM ($P<0.05$).

ns: not significant as compared with Ca²⁺ 200 μM ($P>0.05$).

Several investigations have mentioned that different pathological states might benefit from exogenous CA supplementation (44, 50-52). The protective effects of this peptide against nervous system disorders, aging, cardiovascular complications, and xenobiotic-induced organ injury have been reported (44, 50-52). As mentioned, CA is a well-known antioxidant and scavenger of reactive intermediates (5, 44, 53, 54). This peptide is also reported to boost antioxidant defense mechanisms and preserve cellular glutathione reservoirs (17, 50, 55). CA could efficiently protect biological targets (e.g., DNA, biomembranes lipid) against reactive species (3, 9). Although the antioxidant and reactive species scavenging properties of CA might play a significant role in its protective effects, the exact mechanism of protection provided by this peptide has not been precisely cleared in most cases. The data obtained from the current study revealed that cellular mitochondria is also a critical target for the cytoprotection provided by

CA.

The involvement of CA in the regulation of mitochondria-mediated cell death has been previously mentioned in different experimental models (21-23). The data obtained from the current study revealed that carnosine (0.01 mM- 10 mM) can effectively preserve mitochondrial functionality against Ca²⁺ overload as a universal mechanism involved in mitochondria-mediated cell death (24).

The buffering capacity of CA has been mentioned as an essential feature of this peptide (56). It has been established that CA preserves cellular pH at its physiological level and prevents cell injury (56, 57). Physiologically, the buffering activity of CA becomes crucial in highly active tissues such as skeletal muscles where the acidification of the cellular environment commonly takes place (56, 57). On the other hand, it has been proposed that CA buffering capacity might play a role in enhancing mitochondrial functionality (23). Previous studies indicate that carnosine efficiently




Figure 4. A schematic representation of the effect of carnosine on cellular mitochondria. The mitochondria protection or mitochondria dysfunction depends on the carnosine concentration. ETC: Electron Transfer Chain; mPT: Mitochondrial Permeability Transition.

preserves mitochondrial membrane potential (23, 58). Mitochondrial pH gradient and membrane potential are essential factors for mitochondrial function (23). Hence, chemicals which are capable of localizing in the cellular mitochondria and regulating matrix pH can conserve mitochondrial membrane potential. It has been found that CA might play a role in mitochondrial matrix pH regulation (23). In the current study, we found that mitochondrial membrane potential, as an index of H^+ gradient, was higher in CA-treated mitochondria (0.01-10 mM) (Figure 1). The buffering property of carnosine might help preserve the proper function of mitochondrial matrix localized enzymes. All these findings could indicate the importance of CA in regulating mitochondrial function and energy metabolism.

As mentioned, the relevance of mitochondrial protecting properties of carnosine against xenobiotic-induced toxicity has been proposed in different previous investigations (1, 2, 18-20). It has been mentioned that this peptide prevents oxidative stress, apoptosis, and cell death in different experimental models (19, 59-63). However, the direct effect of various concentrations of carnosine on mitochondria is obscure. In the current investigation, we found that carnosine prevented mi-

tochondrial dysfunction against Ca^{2+} overload as the major cellular signaling molecule responsible for mitochondrial dysfunction and its associated events (24). Hence, carnosine might be applicable not only against xenobiotic-induced mitochondrial dysfunction (33, 64-70) but also against a wide range of mitochondria-linked diseases.

Previous investigations applied very high and possibly biologically-irrelevant concentrations/doses of CA (71-73). It may be possible to design more efficient similar structures which affect cellular mitochondria and energy metabolism. On the other hand, efficient mitochondria-targeting drug delivery systems might help deliver CA to the cellular power plants. Such investigations might help conquer CA bioavailability obstacles and develop carnosine and its similar structures as promising therapeutic agents against mitochondria-linked disorders.

Collectively, our data suggest cellular mitochondria as an essential target for the cytoprotective properties of CA. Indeed further research on the effects of CA on different mitochondrial components will enhance our understanding about the pleiotropic pharmacological properties of this naturally occurring peptide.

Acknowledgements

This work was supported by Pharmaceutical Sciences Research Center and the Office of Vice Chancellor of Research Affairs of Shiraz University of Medical Sciences (Grant: #15034). The authors would like to thank Pharmaceutical

Sciences Research Center of Shiraz University of Medical Sciences for technical facility providing of this study.

Conflict of Interest

None declared.

5. References

- Budzeń S, Rymaszewska J. The biological role of carnosine and its possible applications in medicine. *Adv Clin Exp Med*. 2013;22:739-44.
- Hipkiss AR, Preston JE, Himsworth DTM, Worthington VC, Keown M, Michaelis J, et al. Pluripotent Protective Effects of Carnosine, a Naturally Occurring Dipeptide. *Ann N Y Acad Sci*. 1998;854:37-53.
- Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and Carnosine-Related Antioxidants: A Review. *Curr Med Chem*. 2005;12:2293-315.
- Hipkiss AR. Carnosine and its possible roles in nutrition and health. *Adv Food Nutr Res*. 2009;57:87-154.
- Stvolinsky SL, Kukley ML, Dobrota D, Matejovicova M, Tkac I, Boldyrev AA. Carnosine: an endogenous neuroprotector in the ischemic brain. *Cell Mol Neurobiol*. 1999;19:45-56.
- Boldyrev A, Gallant S, Sukhich G. Carnosine, the protective, anti-aging peptide. *Biosci Rep*. 1999;19:581-7.
- Boldyrev AA. Carnosine: new concept for the function of an old molecule. *Biochemistry (Mosc)*. 2012;77:313-26.
- Bonfanti L, Peretto P, De Marchis S, Fasolo A. Carnosine-related dipeptides in the mammalian brain. *Prog Neurobiol*. 1999;59:333-53.
- Hipkiss AR. Chapter 3 Carnosine and Its Possible Roles in Nutrition and Health. In: Research BTAiF, Nutrition, editors. 57: Academic Press; 2009. p. 87-154.
- Aydın AF, Küçükgergin C, Özdemirler-Erata G, Koçak-Toker N, Uysal M. The effect of carnosine treatment on prooxidant-antioxidant balance in liver, heart and brain tissues of male aged rats. *Biogerontology*. 2009;11:103-9.
- Fu H, Katsumura Y, Lin M, Muroya Y, Hata K, Fujii K, et al. Free radical scavenging and radioprotective effects of carnosine and anserine. *Radiat Phys Chem*. 2009;78:1192-7.
- Kohen R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. *Proc Natl Acad Sci U S A*. 1988;85:3175-9.
- Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. l-carnosine (β -alanyl-l-histidine) and carcinine (β -alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. *Biochem J*. 1994;304:509-16.
- Lee JW, Miyawaki H, Bobst EV, Hester JD, Ashraf M, Bobst AM. Improved Functional Recovery of Ischemic Rat Hearts due to Singlet Oxygen Scavengers Histidine and Carnosine. *J Mol Cell Cardiol*. 1999;31:113-21.
- Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A Versatile Antioxidant and Antigliating Agent. *Sci Aging Knowledge Environ*. 2005;2005:pe12.
- Aldini G, Facino RM, Beretta G, Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives. *BioFactors*. 2005;24:77-87.
- Jamshidzadeh A, Heidari R, Ramezani M, Khodaei F, Ommati MM, et al. Antimalarial Drugs-Induced Hepatic Injury in Rats and the Protective Role of Carnosine. *Pharm Sci*. 2016;22:170-80.
- Heidari R, Niknahad H, Jamshidzadeh A, Azarpira N, Bazyari M, Najibi A. Carbonyl traps as potential protective agents against methimazole-induced liver injury. *J Biochem Mol Toxicol*. 2015;29:173-81.
- Jamshidzadeh A, Heidari R, Latifpour Z, Ommati MM, Abdoli N, Mousavi S, et al. Carnosine ameliorates liver fibrosis and hyperammonemia in cirrhotic rats. *Clin Res Hepatol Gastroenterol*. 2017;41:424-34.
- Jamshidzadeh A, Niknahad H, Heidari R, Zarei M, Ommati MM, Khodaei F. Carnosine protects brain mitochondria under hyperammonemic conditions: Relevance to hepatic encephalopathy treatment. *PharmaNutrition*. 2017;5:58-63.
- Baek S-H, Noh AR, Kim K-A, Akram M, Shin Y-J, Kim E-S, et al. Modulation of Mitochondrion

drial Function and Autophagy Mediates Carnosine Neuroprotection Against Ischemic Brain Damage. *Stroke*. 2014;45:2438-43.

22. Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M, et al. Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. *PLoS One*. 2011;6:e17971.

23. Hansen SH, Andersen ML, Cornett C, Gradinaru R, Grunnet N. A role for taurine in mitochondrial function. *J Biomed Sci*. 2010;17:1-8.

24. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu S-S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *Am J Physiol*. 2004;287:C817-C833.

25. Caro AA, Adlong LW, Crocker SJ, Gardner MW, Luikart EF, Gron LU. Effect of garlic-derived organosulfur compounds on mitochondrial function and integrity in isolated mouse liver mitochondria. *Toxicol Lett*. 2012;214:166-74.

26. Zhao P, Kalthorn TF, Slattery JT. Selective mitochondrial glutathione depletion by ethanol enhances acetaminophen toxicity in rat liver. *Hepatology*. 2002;36:326-35.

27. Tomasskovic B, Szarka A, editors. Comparison of Mannitol and Xylitol as Osmolytes in Preparation of Mitochondria. 5th European Conference of the International Federation for Medical and Biological Engineering; 2011: Springer:1362-5.

28. Jamshidzadeh A, Heidari R, Abasvali M, Zarei M, Ommati MM, Abdoli N, et al. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia. *Biomed Pharmacother*. 2017;86:514-520.

29. Akram J, Hossein N, Reza H, Maryam A, Forouzan K, Mohammad Reza A, et al. Propylthiouracil-induced mitochondrial dysfunction in liver and its relevance to drug-induced hepatotoxicity. *Pharm Sci*. 2017;23:95-102.

30. Niknahad H, Jamshidzadeh A, Heidari R, Abdoli N, Mehdi M, Ommati FJ, et al. The Postulated Hepatotoxic Metabolite of Methimazole Causes Mitochondrial Dysfunction and Energy Metabolism Disturbances in Liver. *Pharm Sci*. 2016;22:217-26.

31. Marroquin L, Swiss R, Will Y. Identifying Compounds that Induce Opening of the Mitochon-

drial Permeability Transition Pore in Isolated Rat Liver Mitochondria. *Curr Protoc Toxicol*: John Wiley & Sons, Inc.; 2001.

32. Niknahad H, Jamshidzadeh A, Heidari R, Hosseini Z, Mobini K, Khodaei F, et al. Paradoxical effect of methimazole on liver mitochondria: In vitro and in vivo. *Toxicol Lett*. 2016;259:108-15.

33. Heidari R, Jafari F, Khodaei F, Shirazi Yeganeh B, Niknahad H. The Mechanism of Valproic Acid-Induced Fanconi Syndrome Involves Mitochondrial Dysfunction and Oxidative Stress in Rat Kidney. *Nephrology (Carlton)*. 2017 Jan 31.

34. Ommati MM, Heidari R, Jamshidzadeh A, Zamiri MJ, Sun Z, Sabouri S, et al. Dual effects of sulfasalazine on rat sperm characteristics, spermatogenesis, and steroidogenesis in two experimental models. *Toxicol Lett*. 2018;284:46-55.

35. Held P. Luminescent Determination of ATP Concentrations Using the Clarity™ Luminescence Microplate Reader. *Nat Methods*. 2006.

36. Ommati MM, Tanideh N, Rezakhaniha B, Wang J, Sabouri S, Vahedi M, et al. Is immunosuppression, induced by neonatal thymectomy, compatible with poor reproductive performance in adult male rats? *Andrology*. 2018;6:199-213.

37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analyt Biochem*. 1976;72:248-54.

38. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65:55-63.

39. Heidari R, Ghanbarinejad V, Mohammadi H, Ahmadi A, Ommati MM, Abdoli N, et al. Mitochondria protection as a mechanism underlying the hepatoprotective effects of glycine in cholestatic mice. *Biomed Pharmacother*. 2018;97:1086-95.

40. Niknahad H, Heidari R, Mohammadzadeh R, Ommati MM, Khodaei F, Azarpira N, et al. Sulfasalazine induces mitochondrial dysfunction and renal injury. *Ren Fail*. 2017;39:745-53.

41. Heidari R, Jamshidzadeh A, Niknahad H, Mardani E, Ommati MM, Azarpira N, et al. Effect of taurine on chronic and acute liver injury: Focus on blood and brain ammonia. *Toxicol Rep*. 2016;3:870-9.

42. Heidari R, Moezi L, Asadi B, Ommati MM, Azarpira N. Hepatoprotective effect of bol-

- dine in a bile duct ligated rat model of cholestasis/cirrhosis. *PharmaNutrition*. 2017;5:109-17.
43. Heidari R, Ghanbarinejad V, Mohammadi H, Ahmadi A, Esfandiari A, Azarpira N, et al. Dithiothreitol supplementation mitigates hepatic and renal injury in bile duct ligated mice: Potential application in the treatment of cholestasis-associated complications. *Biomed Pharmacother*. Dithiothreitol supplementation mitigates hepatic and renal injury in bile duct ligated mice: Potential application in the treatment of cholestasis-associated complications. 2018;99:1022-32.
44. Bellia F, Vecchio G, Cuzzocrea S, Calabrese V, Rizzarelli E. Neuroprotective features of carnosine in oxidative driven diseases. *Mol Aspects Med*. 2011;32:258-66.
45. Prokopieva VD, Yarygina EG, Bokhan NA, Ivanova SA. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies. *Oxid Med Cell Longev*. 2016;2016:2939087.
46. Shumaev KB, Kosmachevskaya OV, Nasybullina EI, Gromov SV, Novikov AA, Topunov AF. New dinitrosyl iron complexes bound with physiologically active dipeptide carnosine. *J Biol Inorg Chem*. 2017;22:153-60.
47. Hasanein P, Felegari Z. Chelating effects of carnosine in ameliorating nickel-induced nephrotoxicity in rats. *Can J Physiol Pharmacol*. 2017;95:1426-32.
48. Sale C, Saunders B, Harris RC. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. *Amino Acids*. 2010;39:321-33.
49. Baguet A, Everaert I, Naeyer HD, Reynhoudt H, Stegen S, Beeckman S, et al. Effects of sprint training combined with vegetarian or mixed diet on muscle carnosine content and buffering capacity. *Eur J Appl Physiol*. 2011;111:2571-80.
50. Rajanikant GK, Zemke D, Senut M-C, Frenkel MB, Chen AF, Gupta R, et al. Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. *Stroke*. 2007;38:3023-31.
51. Boldyrev AA, Aldini G, Derave W. Physiology and Pathophysiology of Carnosine. *Physiol Rev*. 2013;93:1803-45.
52. Evran B, Karpuzoğlu H, Develi S, Kalaz EB, Soluk-Tekkeşin M, Olgaç V, et al. Effects of carnosine on prooxidant-antioxidant status in heart tissue, plasma and erythrocytes of rats with isoproterenol-induced myocardial infarction. *Pharmacol Rep*. 2014;66:81-6.
53. Lopachev AV, Lopacheva OM, Abaimov DA, Koroleva OV, Vladychenskaya EA, Erukhimovich AA, et al. Neuroprotective effect of carnosine on primary culture of rat cerebellar cells under oxidative stress. *Biochemistry (Mosc)*. 2016;81:511-20.
54. Baye E, Ukropcova B, Ukropec J, Hipkiss A, Aldini G, Courten Bd. Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. *Amino Acids*. 2016;48:1131-49.
55. Kim J, Padanilam BJ. Loss of poly (ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. *Am J Physiol Renal Physiol*. 2011;301:F450-F459.
56. Begum G, Cunliffe A, Leveritt M. Physiological Role of Carnosine in Contracting Muscle. *Int J Sport Nutr Exerc Metab*. 2005;15:493-514.
57. Harris RC, Marlin DJ, Dunnett M, Snow DH, Hultman E. Muscle buffering capacity and dipeptide content in the Thoroughbred horse, Greyhound dog and man. *Comp Biochem Physiol A Comp Physiol*. 1990;97:249-51.
58. Shen Y, He P, Fan Y-y, Zhang J-x, Yan H-j, Hu W-w, et al. Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity. *Free Radical Biol Med*. 2010;48:727-35.
59. Afshin-Majd S, Khalili M, Roghani M, Mehranmehr N, Baluchnejadmojarad T. Carnosine Exerts Neuroprotective Effect Against 6-Hydroxydopamine Toxicity in Hemiparkinsonian Rat. *Mol Neurobiol*. 2014;51:1064-70.
60. Cheng J, Wang F, Yu D-F, Wu P-F, Chen J-G. The cytotoxic mechanism of malondialdehyde and protective effect of carnosine via protein cross-linking/mitochondrial dysfunction/reactive oxygen species/MAPK pathway in neurons. *Eur J Pharmacol*. 2011;650:184-94.
61. Riedl E, Pfister F, Braunagel M, Brinkkötter P, Sternik P, Deinzer M, et al. Carnosine Prevents Apoptosis of Glomerular Cells and Podocyte Loss in STZ Diabetic Rats. *Cell Physiol Biochem*. 2011;28:279-88.
62. Xie R-X, Li D-W, Liu X-C, Yang M-F, Fang J, Sun B-L, et al. Carnosine Attenuates Brain Oxidative Stress and Apoptosis After Intracerebral Hemorrhage in Rats. *Neurochem Res*. 2017;42:541-51.

63. Zhang Z-y, Sun B-l, Yang M-f, Li D-w, Fang J, Zhang S. Carnosine attenuates early brain injury through its antioxidative and anti-apoptotic effects in a rat experimental subarachnoid hemorrhage model. *Cell Mol Neurobiol.* 2015;35:147-57.
64. Heidari R, Babaei H, Eghbal M. Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes. *Drug Chem Toxicol.* 2012;36:403-11.
65. Heidari R, Babaei H, Eghbal M. Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. *Res Pharm Sci.* 2014;9:97-105.
66. Niknahad H, Heidari R, Alzuhairi AM, Najibi A. Mitochondrial Dysfunction as a Mechanism for Pioglitazone-Induced Injury toward HepG2 Cell Line. *Pharm Sci.* 2015;20:169-74.
67. Heidari R, Babaei H, Eghbal MA. Cytoprotective Effects of Taurine Against Toxicity Induced by Isoniazid and Hydrazine in Isolated Rat Hepatocytes. *Arh Hig Rada Toksikol.* 2013;64:15-24.
68. Abdoli N, Heidari R, Azarmi Y, Eghbal MA. Mechanisms of the Statins Cytotoxicity in Freshly Isolated Rat Hepatocytes. *J Biochem Mol Toxicol.* 2013;27:287-94.
69. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. *Cell Biol Toxicol.* 1999;15:367-73.
70. Monsalve M, Borniquel S, Valle I, Lamas S. Mitochondrial dysfunction in human pathologies. *Biochem Soc Trans.* 2017;45:1213-23.
71. Bao Y, Ding S, Cheng J, Liu Y, Wang B, Xu H, et al. Carnosine Inhibits the Proliferation of Human Cervical Gland Carcinoma Cells Through Inhibiting Both Mitochondrial Bioenergetics and Glycolysis Pathways and Retarding Cell Cycle Progression. *Integr Cancer Ther.* 2018;17:80-91.
72. Holliday R, McFarland GA. Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine. *Br J Cancer.* 1996;73:966-71.
73. Zhang Z, Miao L, Wu X, Liu G, Peng Y, Xin X, et al. Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling. *J Cancer.* 2014;5:382-9.